All In Biotech

NDA 021903 · Recordati Rare

Neoprofen

Ibuprofen Lysine · Intravenous

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Oct 25, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Apr 13, 2006

Approved uses

1

Original approval plus efficacy supplements

Registered trials

898

160 Phase 3, 60 recruiting

FAERS reports

569

553 serious, 94 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 6, 2026.

Ibuprofen Lysine is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conducted among infants with an asymptomatic PDA. However, the consequences beyond 8 weeks after treatment have not been evaluated; therefore, treatment should be reserved for infants with clear evidence of a clinically significant PDA. Ibuprofen Lysine is a nonsteroidal anti-inflammatory drug indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management is ineffective. The clinical trial was conducted among infants with an asymptomatic PDA. However, the consequences beyond 8 weeks after treatment have not been evaluated; therefore, treatment should be reserved for infants with clear evidence of a clinically significant PDA. (1)

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 13, 2006 Original approval · Type 2 - New Active Ingredient · priority review OrphanLabelReview
1 products under this application
  • NEOPROFEN · IBUPROFEN LYSINE EQ 20MG BASE/2ML (EQ 10MG BASE/ML) · INJECTABLE, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Ibuprofen Lysine" as an intervention, any sponsor and status, largest first.

All 898 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • bronchopulmonary dysplasia113
  • intraventricular haemorrhage34
  • necrotising colitis30
  • gastrointestinal perforation29
  • completed suicide27
  • anaemia25
  • hyponatraemia25
  • intestinal perforation25
  • urine output decreased23
  • death20
  • pulmonary haemorrhage20
  • posthaemorrhagic hydrocephalus19

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200628
200737
200845
20096
20102
20116
2012150
20132
20143
201523
201624
20173
20189
201939
202028
202142
202226
202318
202455
202516
20267

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 18 on PubMed

Sponsor: Recordati Rare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.